Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
L Van Neste, R Henao, KJ Wojno, J Signes… - The Journal of …, 2024 - auajournals.org
Purpose: Less invasive decision support tools are desperately needed to identify occult high-
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
[PDF][PDF] Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
L Van Neste, R Henao, KJ Wojno, J Signes… - Journal of …, 2023 - journals.lww.com
Methods: Men were eligible for enrollment in the study if they were determined by their
physician to have a risk profile that warranted prostate biopsy. Both training (n= 1017) and …
physician to have a risk profile that warranted prostate biopsy. Both training (n= 1017) and …
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
L Van Neste, R Henao, KJ Wojno… - The Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose Less invasive decision support tools are desperately needed to identify occult high-
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
L Van Neste, R Henao, KJ Wojno, J Signes… - Journal of …, 2024 - ingentaconnect.com
Purpose: Less invasive decision support tools are desperately needed to identify occult high-
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
L Van Neste, R Henao, KJ Wojno, J Signes… - The Journal of …, 2023 - europepmc.org
Methods Men were eligible for enrollment in the study if they were determined by their
physician to have a risk profile that warranted prostate biopsy. Both training (n= 1017) and …
physician to have a risk profile that warranted prostate biopsy. Both training (n= 1017) and …
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
L Van Neste, R Henao, KJ Wojno… - The Journal of …, 2023 - scholarlyworks.beaumont.org
PURPOSE: Less invasive decision support tools are desperately needed to identify occult
high-risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a …
high-risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a …
[HTML][HTML] Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification
L Van Neste, R Henao, KJ Wojno, J Signes… - Journal of …, 2024 - journals.lww.com
Purpose: Less invasive decision support tools are desperately needed to identify occult high-
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a variety of …
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
L Van Neste, R Henao, KJ Wojno… - Journal of …, 2024 - scholarlyworks.beaumont.org
PURPOSE: Less invasive decision support tools are desperately needed to identify occult
high-risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a …
high-risk disease in men with prostate cancer (PCa) on active surveillance (AS). For a …